Research programme: cell based inflammatory bowel disease therapeutics: Icahn School of Medicine/Takeda/University of Chicago
Latest Information Update: 20 Apr 2016
At a glance
- Originator Icahn School of Medicine at Mount Sinai; Takeda Pharmaceuticals USA; University of Chicago
- Class Cell therapies
- Mechanism of Action Immunomodulators; Inflammation mediator inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Inflammatory bowel diseases